Literature DB >> 1159052

Disappearance rates of plasma growth hormone after intravenous somatostatin in renal and liver disease.

B L Pimstone, D Le Roith, S Epstein, S Kronheim.   

Abstract

Plasma immunoreactive growth hormone (hGH) was measured before, during and after the administration of intravenous somatostatin to 3 patients with chronic renal failure and 4 with severe liver disease who had elevation of basal hGH. During somatostatin infusion, the hGH levels declined acutely in a linear fashion when log hGH was plotted against time. Rather surprisingly, the plasma hGH half disappearance time (t 1/2) was 27 min and 18 min in liver and renal disease respectively. These values do not differ from data obtained on normal subjects using exogenous hGH, labelled or unlabelled. Control data on normal subjects using this technique are not available as it was not possible to measure subnormal levels of plasma hGH with the required precision. It is possible that our findings of plasma hGH T 1/2 in liver and renal disease within the normal range reported using exogenous hGH might suggest that high levels of plasma hGH found in these two diseases are primarily caused by hypersecretion rather than impaired clearance.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1159052     DOI: 10.1210/jcem-41-2-392

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

Review 1.  Disturbance of growth hormone--insulin-like growth factor axis in uraemia. Implications for recombinant human growth hormone treatment.

Authors:  B Tönshoff; F Schaefer; O Mehls
Journal:  Pediatr Nephrol       Date:  1990-11       Impact factor: 3.714

Review 2.  Growth hormone/insulin-like growth factor system in children with chronic renal failure.

Authors:  Burkhard Tönshoff; Daniela Kiepe; Sonia Ciarmatori
Journal:  Pediatr Nephrol       Date:  2005-02-04       Impact factor: 3.714

3.  Hypothalamic-pituitary dopaminergic function in hepatic failure in man.

Authors:  S Lal; M Oravec; A Aronoff; M E Kiely; H Guyda; S Solomon; N P Nair
Journal:  J Neural Transm       Date:  1982       Impact factor: 3.575

Review 4.  Involvement of brain catecholamines and acetylcholine in growth hormone hypersecretory states. Pathophysiological, diagnostic and therapeutic implications.

Authors:  E E Müller; M Rolla; E Ghigo; D Belliti; E Arvat; A Andreoni; A Torsello; V Locatelli; F Camanni
Journal:  Drugs       Date:  1995-11       Impact factor: 9.546

5.  Metabolic clearance of recombinant human growth hormone in health and chronic renal failure.

Authors:  D Haffner; F Schaefer; J Girard; E Ritz; O Mehls
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.